Previous evidence suggests that concurrent occurrence of activators such as TGF-β1 within the evolving tumorous tissue and hypoxic regions could synergistically stimulate VEGF expression, thereby facilitating a suitable milieu for tumor angiogenesis. The gene discussed is TGFB1; the disease is neoplasm.